Explore more publications!
Solomon Islands Health Reporter
Submit Press Release

Solomon Islands Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Solomon Islands Health Reporter.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on October 9, 2025

LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
October 9, 2025

LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025

Indeterminate GlobeNewswire
Portsmouth Square, Inc. Announces FY2025 Results; Going-Concern Doubt Alleviated Following March 2025 Hotel Refinancing and Strong Operating Trends
October 9, 2025

Portsmouth Square, Inc. Announces FY2025 Results; Going-Concern Doubt Alleviated Following March 2025 Hotel Refinancing and Strong Operating Trends

Indeterminate GlobeNewswire
Clover Health Comments on 2026 Medicare Advantage Star Ratings and Trajectory for Increasing Profitability into 2027
October 9, 2025

Clover Health Comments on 2026 Medicare Advantage Star Ratings and Trajectory for Increasing Profitability into 2027

Indeterminate GlobeNewswire
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
October 9, 2025

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Indeterminate GlobeNewswire
Shuttle to Enter $3.24 Billion AI Pharmaceutical Market
October 9, 2025

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Indeterminate GlobeNewswire
Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025
October 9, 2025

Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025

Indeterminate GlobeNewswire
OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance
October 9, 2025

OrthoPediatrics Corp. Announces Preliminary Third Quarter 2025 Revenue and Revised 2025 Guidance

Indeterminate GlobeNewswire
TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran
October 9, 2025

TELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran

Indeterminate GlobeNewswire
Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
October 9, 2025

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Indeterminate GlobeNewswire
The American Journal of Managed Care® congratulates Jane M. Zhu, M.D., MPP, MSHP, on receiving the 2025 Seema S. Sonnad Emerging Leader in Managed Care Research Award
October 9, 2025

The American Journal of Managed Care® congratulates Jane M. Zhu, M.D., MPP, MSHP, on receiving the 2025 Seema S. Sonnad Emerging Leader in Managed Care Research Award

Indeterminate GlobeNewswire
Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
October 9, 2025

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Indeterminate GlobeNewswire
Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant
October 9, 2025

Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant

Indeterminate GlobeNewswire
Childhood Cancer Deserves Year-Round Commitment to Funding and Research
October 9, 2025

Childhood Cancer Deserves Year-Round Commitment to Funding and Research

Indeterminate GlobeNewswire
JOURTHON® Launches Brain Health Softgel
October 9, 2025

JOURTHON® Launches Brain Health Softgel

Indeterminate GlobeNewswire
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
October 9, 2025

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Indeterminate GlobeNewswire
Die ICPO Foundation begrüßt 24 neue ICPO Theranostics Clinical Centers of Excellence in ihrem globalen Netzwerk von nun 45 Centern
October 9, 2025

Die ICPO Foundation begrüßt 24 neue ICPO Theranostics Clinical Centers of Excellence in ihrem globalen Netzwerk von nun 45 Centern

Indeterminate GlobeNewswire
ICPO Foundation welcomes 24 new ICPO Theranostics Clinical Centers of Excellence to its global network of 45 centers
October 9, 2025

ICPO Foundation welcomes 24 new ICPO Theranostics Clinical Centers of Excellence to its global network of 45 centers

Indeterminate GlobeNewswire
Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting, October 18-21 in Orlando
October 9, 2025

Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting, October 18-21 in Orlando

Indeterminate GlobeNewswire
Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer
October 9, 2025

Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer

Indeterminate GlobeNewswire
Optime Care Terminates Distributor Agreement for Korlym® (mifepristone)
October 9, 2025

Optime Care Terminates Distributor Agreement for Korlym® (mifepristone)

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions